The sales are too small to be informative, monitor for larger insider transactions or a cluster of C-suite buys for a real signal. The exercise-and-sell pattern is routine; no immediate trading action warranted.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 9 $45.00entry
- T+1 · 2mo ago −6.13%α −5.53% · $42.24
- T+5 · 2mo ago −4.36%α −4.02% · $43.04
- T+20 · 6w ago −9.56%α −11.75% · $40.70
- T+48 · todayOpen
- T+60 · in 16d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two UroGen Pharma insiders, the Chief Medical Officer and General Counsel, sold a combined $102K in open-market shares on September 8, 2026, following non-cash option exercises the prior day. At a $2.1B market cap, the sales represent ~0.005% of market cap, well below the 0.1% threshold for materiality, and the exercise-and-sell pattern is consistent with routine tax-planning or diversification, not a bearish signal. The cluster is neutral, the dollar amount is trivial relative to company size, and the sales are liquidity-driven.
Key Financial Metrics
Key Facts
- CMO Mark Schoenberg sold 871 shares at $42.92 for $37K on 2026-09-08
- General Counsel Jason Drew Smith sold 1,519 shares at $42.54 for $65K on 2026-09-08
- Both insiders exercised stock options (non-cash) on 2026-09-07 before selling the next day
- Total open-market sales: $102K, or ~0.005% of $2.1B market cap
- No insider buying in the cluster, net direction is selling
Financial Impact
$102K in total insider sales, representing ~0.005% of market cap, trivial
Risk Factors
- Insiders could increase selling volume in future windows
- No insider buying to offset the sales, lack of bullish conviction signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-URGN-1788979067041 |
Track record
16 reports on URGN
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
- Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Viewing Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
- Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers